Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Imaging Studies III: Computed Tomography01:27

Imaging Studies III: Computed Tomography

251
DefinitionComputed Tomography (CT) of the genitourinary (GU) tract is a non-invasive imaging modality that utilizes X-rays and computer processing to generate detailed cross-sectional images of the urinary system, encompassing the kidneys, ureters, bladder, and adjacent structures such as the adrenal glands.PurposeCT scans of the GU tract serve several diagnostic and therapeutic purposes, including:Diagnosis of Urinary Tract Diseases: Detects kidney stones, tumors, cysts, and congenital...
251
Imaging Studies IV: Magnetic Resonance Imaging01:27

Imaging Studies IV: Magnetic Resonance Imaging

212
Introduction:Magnetic Resonance Imaging, or MRI, can include a specialized imaging technique of the urinary system known as Magnetic Resonance Urography (MRU). This radiation-free technique uses strong magnetic fields and radio waves to produce detailed images with the help of a computer. MRU is particularly effective for visualizing fluid-filled structures like the kidneys, ureters, and bladder.Applications of MRI in the Genitourinary SystemKidneys and Ureters: MRI detects tumors, cysts,...
212
Brain Imaging01:14

Brain Imaging

629
Brain imaging technologies provide critical insights into both the structure and function of the human brain, enabling medical professionals and researchers to diagnose, study, and treat neurological disorders or psychiatric disorders more effectively.
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans),  magnetic resonance imaging (MRI),  functional magnetic resonance imaging (fMRI), and Transcranial Magnetic...
629
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

460
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
460
Imaging Studies I: CT and MRI01:14

Imaging Studies I: CT and MRI

758
Introduction: MRI and CT scans are crucial advancements in medical imaging techniques, playing a vital role in diagnosing conditions related to the gastrointestinal (GI) system. Each scan serves distinct purposes, targets specific areas, and requires unique nursing duties.
Description of the Procedures
Computed Tomography (CT) scan:
Computed Tomography (CT) scans use X-ray technology to generate detailed images of bones, organs, and tissues. During the scan, the patient lies on a moving table...
758

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Features predicting data exclusion in imaging studies of Alzheimer's disease.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Blood-based proteomic signature of amyloidosis: identification of novel regulators of amyloid load.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

No cognitive or psychological impact from returning research Alzheimer disease biomarkers: A delayed-start, noninferiority, randomized clinical trial.

medRxiv : the preprint server for health sciences·2026
Same author

Comparison of [18F]flortaucipir and [18F]MK6240 for the detection of tau pathology in Alzheimer's disease (HEAD): a multicentre, prospective, cross-sectional, within-participant study.

Lancet (London, England)·2026
Same author

Elevated functional magnetic resonance imaging activity in cognitively normal participants predicts future dementia.

Brain communications·2026
Same author

Plasma eMTBR-tau243 and %p-tau217 for Biological Staging of Alzheimer Disease.

JAMA neurology·2026
Same journal

Breaking barriers: Enhancing access to dementia clinical trials in the United Kingdom-Insights from the Scientific Advisory Board of the Dame Barbara Windsor Dementia Goals Programme.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
関連記事をすべて見る

関連する実験動画

Updated: Jan 8, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

751

アルツハイマー病イメージングコンソーシアム

Andreia Rocha1, Bruna Bellaver1, Carolina Soares1

  • 1University of Pittsburgh, Pittsburgh, PA, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 23, 2025
PubMed
まとめ
この要約は機械生成です。

4つのタウPETトレーサーは、アルツハイマー病(AD)におけるブラーク病期分類でばらつきを示した。平均的にはトレーサー間で同等であったが、個々の病期分類の不一致は、タウ病理評価において完全に相互交換可能ではないことを意味する。

キーワード:
アルツハイマー病タウPETブラーク病期分類イメージングバイオマーカー

さらに関連する動画

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
09:31

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry

Published on: March 7, 2019

11.0K
Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly
12:50

Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly

Published on: April 14, 2014

40.8K

関連する実験動画

Last Updated: Jan 8, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

751
Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
09:31

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry

Published on: March 7, 2019

11.0K
Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly
12:50

Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly

Published on: April 14, 2014

40.8K

科学分野:

  • 神経画像診断
  • アルツハイマー病研究
  • バイオマーカー開発

背景:

  • ブラーク病期分類システムは、死後検査を用いてアルツハイマー病(AD)におけるタウ病理を分類します。
  • トレーサーの違いにより、陽電子放出断層撮影(PET)イメージングにブラーク病期分類を適応させることは困難です。
  • 本研究では、4つのタウPETトレーサー(Flortaucipir、MK6240、PI2620、RO948)を比較します。

研究 の 目的:

  • アルツハイマー病スペクトラムの個人における4つのタウPETトレーサー間のブラーク病期分類を比較すること。
  • タウ病理の病期分類における系統的なバイアスと異なるタウPETトレーサー間の合意を評価すること。
  • アミロイドβ(Aβ)負荷の関数としてタウPETブラーク領域の軌跡をモデル化すること。

主な方法:

  • Aβ PETおよび4つのタウPETトレーサーを使用した90人の参加者(認知機能正常、MCI、認知症)を評価しました。
  • Aβ陰性の認知機能正常者に基づいてブラーク陽性を定義しました。
  • トレーサーの一致と領域ごとの軌跡を評価するために、Bland-Altman分析とLowessモデリングを採用しました。

主要な成果:

  • タウPETのブラーク病期分類の軌跡は、トレーサーおよびAβ負荷によって著しく異なりました。
  • トレーサーごとに最も早期の異常領域が異なりました(例:MK6240ではブラークI、FlortaucipirではブラークIV)。
  • ブラーク病期分類におけるトレーサーの一致は、ブラーク0またはIV-Vで最も高く、中間段階では一致率が低かったものの、系統的なバイアスは最小限でした。

結論:

  • Flortaucipir、MK6240、PI2620、RO948タウPETトレーサーを比較すると、ブラーク病期分類に不一致が存在します。
  • トレーサーは平均的な比較可能性を示しますが、個々のアルツハイマー病の病期分類には相互に交換可能ではありません。
  • 正確なブラーク病期分類のためにタウPETトレーサーの適用を洗練するには、さらなる研究が必要です。